Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iloperidone
Drug ID BADD_D01134
Description Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Indications and Usage Treatment of acute schizophrenia.
Marketing Status approved
ATC Code N05AX14
DrugBank ID DB04946
KEGG ID D02666
MeSH ID C081732
PubChem ID 71360
TTD Drug ID D0M8VE
NDC Product Code 46016-1332; 43068-102; 51672-4178; 51672-4213; 43068-101; 43068-108; 51672-4180; 50379-0006; 63285-755; 63285-756; 66499-0067; 51672-4182; 0378-0632; 0378-0633; 43068-104; 43068-106; 43068-110; 66499-0042; 51672-4183; 0378-0631; 66022-0115; 43068-901; 51672-4181; 0378-0636; 43068-112; 43068-902; 0378-0634; 0378-0635; 43068-903; 0378-0630; 43068-113; 51672-4179; 51672-4184
UNII VPO7KJ050N
Synonyms iloperidone | Fanapt | HP 873 | HP-873 | Zomaril
Chemical Information
Molecular Formula C24H27FN2O4
CAS Registry Number 133454-47-4
SMILES CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dehydration14.05.05.001--
Delirium19.13.02.001--
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.0070.001529%
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.000889%
Dry throat07.06.01.005; 22.12.03.005--Not Available
Duodenal ulcer07.04.02.002--
Dyskinesia17.01.02.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Dyspnoea exertional02.11.05.005; 22.02.01.005--Not Available
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Ejaculation failure21.03.01.003--Not Available
Endocrine disorder05.09.01.001--Not Available
Enuresis20.02.02.003; 19.07.04.001--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Extrapyramidal disorder17.01.02.0070.000131%
Eye disorder06.08.03.001--Not Available
Eye swelling06.08.03.003--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.0020.000640%
Galactorrhoea05.03.04.002; 21.05.02.0020.000287%Not Available
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene